Novartis Empowers Young Adults with SMA Through 'SMAsh' Advocacy Campaign

Novartis Launches 'SMAsh' Campaign to Empower Young Adults with Spinal Muscular Atrophy Novartis has introduced a new initiative aimed at supporting individuals living with spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder. The campaign, titled 'SMAshing My Limits,' encourages patients to overcome challenges and celebrates their personal milestones. SMA results from the absence of a functional SMN1 gene, leading to progressive loss of motor neurons and impairing muscle functions such as breathing, swallowing, and movement. Approximately 9,500 Americans are affected by this condition. While neonatal screening ensures early detection and access to treatments—available for about seven years—the focus has traditionally been on young children. With advancements in therapy, many teens and young adults are now experiencing longer, more active lives. Recognizing their unique needs, Novartis’s campaign emphasizes empowerment, community connection, and acknowledgment of achievements among older SMA patients. The initiative was inspired by insights from the SMA community, highlighting the significance of everyday milestones that often go unnoticed. Collaborating with ad...